Kura Oncology Inc. (KURA) is a clinical-stage biopharmaceutical company that focuses on the discovery and development of precision medicines for the treatment of cancer. The company's lead product candidate, tipifarnib, is a selective inhibitor of farnesyl transferase currently in Phase 2 and 3 clinical trials for the treatment of various hematologic malignancies and solid tumors. Kura Oncology is also developing KO-539, a small-molecule inhibitor of the menin-MLL protein-protein interaction, which is currently in Phase 1 clinical trials for the treatment of acute leukemia. The company is headquartered in San Diego, California. As of September 2021, Kura Oncology had a market capitalization of approximately $2.42 billion.
Kura Oncology Inc. (KURA) is a clinical-stage biopharmaceutical company that focuses on the discovery and development of precision medicines for the treatment of cancer. The company's lead product candidate, tipifarnib, is a selective inhibitor of farnesyl transferase currently in Phase 2 and 3 clinical trials for the treatment of various hematologic malignancies and solid tumors. Kura Oncology is also developing KO-539, a small-molecule inhibitor of the menin-MLL protein-protein interaction, which is currently in Phase 1 clinical trials for the treatment of acute leukemia. The company is headquartered in San Diego, California. As of September 2021, Kura Oncology had a market capitalization of approximately $2.42 billion.